Efficacy of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir with Ribavirin in Liver Transplant Recipients with Recurrent HCV GT1
The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific
0 views • 8 slides
Daclatasvir + Sofosbuvir + Ribavirin in HCV GT-3 Advanced Liver Disease: ALLY-3+ Trial
The ALLY-3+ Trial investigates the efficacy of daclatasvir, sofosbuvir, and ribavirin in patients with chronic HCV GT-3 and advanced liver disease. This Phase 3 study compared 12 versus 16 weeks of treatment in treatment-naive or experienced individuals. Results showed promising SVR12 rates and favo
0 views • 9 slides